ACC 2017 In AF patients undergoing ablation, periprocedural anticoagulation with uninterrupted dabigatran (150 mg twice daily) compared with warfarin was associated with fewer bleeding complications.
ACC 2017 The REACH trial demonstrated that after 12 months of use of an e-counselling programme, hypertensives showed 10 mmHg lower SBP and improvement of other risk factors.
ACC 2017 In the EINSTEIN CHOICE study, rivaroxaban, at both 20 mg and 10 mg doses, was more effective than aspirin for the prevention of recurrent venous thromboembolism after 6 to 12 months of therapy.
ACC 2017 In STEMI patients with multi-vessel disease, fractional flow reserve-guided complete revascularisation of non–infarct-related lesions during primary PCI, reduced the risk of MACCE.
ACC 2017 In post-ACS patients with at least one site with percent atheroma volume >30% in the proximal 10 mm of the target vessel, CER-001 did not lead to significant plaque regression in the CARAT study.
ACC 2017 A safety study of rivaroxaban versus aspirin on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding.
ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.
ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.
ACC 2017 Inclisiran, which prevents PCSK9 protein production, resulted in long-term LDL-c lowering after two doses of siRNA, without safety concerns, in the ORION-1 study.
ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.
ACC 2017 The SPIRE trial data show that treatment with bococizumab resulted in LDL-c lowering that was not stable over time, due to generation of anti-drug antibodies.
ACC 2017 The FOURIER trial showed stable LDL-c reduction with evolocumab during 3 years in statin-treated CVD patients, and lower CV event rates. Event curves continued to diverge over time.